Quinone-based therapeutic agent for hepatopathy

Details Quinone-based therapeutic agent for hepatopathy Quinone-based therapeutic agent for hepatopathy

2006-11-21

2006-11-21

Henley, III, Raymond J. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ketone doai

Reexamination Certificate

active

07138433

ABSTRACT:
With an object of providing an agent for treating hepatic disease by inhibiting occurrence of hepatic disease, in particular portal venous invasion, there is disclosed an agent for treating or preventing hepatic disease containing menatetrenone as an active ingredient thereof. This agent for treating or preventing hepatic disease is effective against hepatic cancer, in particular DCP (des-γ-carboxy prothrombin) positive hepatic cancer. Moreover, the agent for treating or preventing hepatic disease containing menatetrenone as an active ingredient thereof according to the present invention exhibits remarkable effects in improving the prognosis after hepatic cancer treatment, and exhibits excellent effects as an agent for inhibiting the recurrence of hepatic cancer.

REFERENCES:
patent: 5021570 (1991-06-01), Ida et al.
patent: 63-185921 (1988-08-01), None
patent: 06-305955 (1994-11-01), None
STN Registry File Monograph, RN 863-61-6 (2004).
Johnson et al., “Relationship Between Drug Activity in NCI Preclinical In Vitro and In Vivo Models and Early Clinical Trials”, British Journal of Cancer, (2001) 84(10); 1424-1431.
“Comparison of Antitumor Activity of Vitamins K1, K2and K3on Human Tumor Cells By Two (MTT and SRB) Cell Viability Assays,” Felicia Y. - H. Wu et al., Life Sciences, vol. 52 pp. 1797-1804, Pergamon Press 1993.
“Changes of Plasma Des-y-Carboxy Prothrombin Levels In Patients With Hepatocellular Carcinoma In Repsonse to Vitamin K,” Midori Furukawa et al., Cancer, vol. 69, No. 1, pp. 31-38, J.B. Lippincott Company, Philadelphia, Jan. 1, 1992.
“DES-y-Carboxy Prothrombin As A Useful Predisposing Factor for the Development of Portal Venous Invasion in Patients with Hepatocellular Carcinoma,” Yukihiro Koike et al., Cancer, vol. 91, No. 3, pp. 561-569, John Wiley & Sons, Inc., Feb. 1, 2001.
“The Growth Inhibitory Effects of Vitamins K and Their Actions On Gene Expression,” Ziqiu Wang et al., Hepatology, vol. 22, pp. 876-882, Sep. 1995.
O'Neil, J.M. et al., The Merck Index Thirteenth Edition, Merck & Co., Inc., 2001 p. 1787, Item 10082 on Vitamin K.
38thAnnual Meeting of Liver Cancer Study Group of Japan, Item 110, p. 135, Inhibitory Effect of Vitamin K Injection Against the Recurrence of Hepatocellular Carcinoma, published on May 13, 2002.
Japanese Journal of Gastroenterology, vol. 99 Supplement, Mar. 20, 2002, Item 308, A Clinical Study of the Effects of Vitamin K in Inhibiting Recurrence of Hepatocellular Carcinoma.
ACTA Hepatologica Japonica, vol. 43 Supplement (1) 2002, May 20, 2003, Item O-98, A Randomized Prospective Controlled Study by Vitamin K-II Injection for the Purpose of Preventing Portal Venous Invasion (PVI).
Koike, Y. et al.., “Randomized Prospective Study of Prevention from Tumor Invasion into Portal Vein in 120 Patients with Hepatocellular Carcinoma by Vitamin K Administration,” available online at: http://ddw02.agora.com/planner/displayabstract.asp?presentationid=31 (Apr. 11, 2002).
Copy of Official Action for Russian Application No. 2004136304-15 (039482), Russian Patent and Trademark Office, dated Mar. 29, 2006.
Unverified English translation of Official Action for Russian Application No. 2004136304-15 (039482) (Document AK2) (date not availabe).

Affiliated with

Also associated with

Rating

Quinone-based therapeutic agent for hepatopathy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinone-based therapeutic agent for hepatopathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinone-based therapeutic agent for hepatopathy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3673187